Tag

Cardiovascular Events

All articles tagged with #cardiovascular events

health15 days ago•4 min saved

VA data suggest COVID boosters curb heart risk in older veterans

A study using US Veterans Affairs records found the 2024-2025 COVID vaccine, given with the flu vaccine on the same day, was associated with lower risk of COVID-related major adverse cardiovascular events (MACE) in more than one million veterans, particularly those 75 and older and with underlying conditions. Within eight months, relative vaccine effectiveness was 37.7% for all MACE, including a 57.9% lower risk of cardiovascular death, 38.5% lower risk of heart attack, and 41.9% lower risk of hospitalization for heart failure; stroke reduction was not statistically significant. The study is observational and cannot prove causation, and declines in COVID testing and infection severity may affect the links observed.

via New York Post|

#cardiovascular-events #covid-vaccine #health

health19 days ago•36 min saved

Veterans Study Finds COVID Vaccine Lowers Heart Risks in Older Adults

A large study of more than 1 million U.S. veterans found the 2024–2025 COVID-19 vaccine was linked to fewer major adverse cardiovascular events in the following eight months, with about a 38% drop in COVID-related cardiac events and a 24% drop in all-cause cardiac events—especially among those aged 75+ or with chronic conditions—suggesting updated vaccines may offer broader protection beyond preventing COVID symptoms.

via Yahoo Lifestyle Canada|

#cardiovascular-events #covid-19-vaccine #health

health1 month ago•4 min saved

Muscle Mass Decline and Visceral Fat Linked to CKD Outcomes in Stage 3 Patients

In a prospective UK cohort of 1,732 stage 3 CKD patients, lower creatinine muscle index (CMI) was tied to higher all-cause mortality and CKD progression over 5 years, while higher waist-to-hip ratio (WHR) predicted more cardiovascular events; age, male sex, higher urine albumin:creatinine ratio, and lower serum albumin also increased risk.

via Medscape|

#cardiovascular-events #ckd #health

health2 months ago•6 min saved

Long Covid May Damage Hearts: New Lancet Findings Highlight Cardiac Risk

A Lancet study from Sweden’s Karolinska Institute finds that Long Covid can damage the heart, with about 18% of women reporting a cardiovascular event and evidence the condition may disrupt autonomic nervous system function, underscoring growing concerns about lasting cardiac risk among those affected.

via The Irish Times|

#autonomic-nervous-system #cardiovascular-events #health

health10 months ago•3 min saved

New Blood Thinner Outperforms Aspirin in Heart Attack Prevention

Doctors have discovered that clopidogrel is more effective than aspirin in preventing heart attacks and strokes in patients with coronary artery disease, without increasing bleeding risks, potentially leading to a change in global treatment guidelines.

via The Guardian|

#aspirin #cardiovascular-events #clopidogrel

health2 years ago•0 min saved

Ozempic Significantly Reduces Risks in Kidney Disease and Diabetes, Study Shows

Novo Nordisk's semaglutide significantly reduced the risk of major cardiovascular events and death in patients with type 2 diabetes and chronic kidney disease in a Phase 3 study, supporting its potential for broader indications. The results were presented at the European Renal Association's conference and published in the New England Journal of Medicine.

via Endpoints News|

#cardiovascular-events #chronic-kidney-disease #health

health-cardiology2 years ago•2 min saved

Excessive Niacin Linked to Increased Risk of Heart Disease

Excess niacin metabolism was found to be associated with major adverse cardiovascular events (MACE), with two breakdown products, 2PY and 4PY, showing a strong link to myocardial infarction, stroke, and other adverse cardiac events. The study suggests that niacin supplementation may require a more nuanced, titrated approach to avoid excess 4PY generation, which is associated with increased MACE risk. The findings highlight the potential impact of niacin levels on cardiovascular health and the need for careful consideration of niacin supplementation.

via Medscape|

#cardiovascular-events #genetic-analysis #health-cardiology

health2 years ago•4 min saved

Wegovy: The Weight Loss Drug with Significant Heart Benefits

A large international study has found that the weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in individuals with heart disease but without diabetes. The study is the first to demonstrate that an obesity medication can not only help with weight loss but also safely prevent heart attacks, strokes, and heart-related deaths. The findings could change treatment guidelines and put pressure on health insurers to cover these medications, shifting the perception that they are solely cosmetic treatments. Wegovy is a high-dose version of the diabetes treatment Ozempic and has already been shown to reduce heart risks in people with diabetes.

via KSL.com|

#cardiovascular-events #health #heart-problems

health2 years ago•7 min saved

Optimal Revascularization Approach for Elderly MI Patients: Complete is Key

The FIRE trial presented at the European Society of Cardiology Congress 2023 showed that complete revascularization, as opposed to treating only the culprit lesion, reduced the risk of cardiovascular events, including death and myocardial infarction, in elderly patients aged 75 and older presenting with either STEMI or NSTEMI. The trial demonstrated that complete revascularization guided by functional testing was safe and beneficial in this population, challenging the current practice of treating only the culprit lesion. The results highlight the need to consider complete revascularization in older patients with multivessel disease and may lead to a shift in clinical practice towards a more comprehensive approach.

via TCTMD|

#cardiovascular-events #clinical-practice #complete-revascularization

health2 years ago•2 min saved

Semaglutide: A Weight Loss Wonder Drug that Saves Lives

A study conducted by the University of California, Irvine, and partly funded by Novo Nordisk, suggests that the weight loss injection Wegovy could prevent up to 1.5 million heart attacks, strokes, and other cardiovascular events in the U.S. over a 10-year period. The study also found that Wegovy could result in 43 million fewer Americans with obesity. These findings align with previous data from a clinical trial, which showed that Wegovy reduced the risk of serious heart problems and heart-related death by 20%. The results indicate that Wegovy and similar obesity drugs have significant health benefits beyond weight loss, potentially increasing pressure on insurers to cover these medications.

via CNBC|

#cardiovascular-events #health #novo-nordisk

health2 years ago•4 min saved

Wegovy's groundbreaking trial result may revolutionize health insurance access

The results of a late-stage trial for the weight-loss drug Wegovy have shown that it reduces the risk of major cardiovascular events by 20%, which could lead to increased access to the drug through health insurance schemes. Novo Nordisk, the pharmaceutical company behind Wegovy, plans to seek regulatory approval to add cardiovascular benefits to the drug label. Analysts believe that the trial results could change the perception of Wegovy from a vanity drug to one that health insurers are willing to cover. However, supply constraints and reports of side effects may pose challenges to the drug's availability.

via CNBC|

#cardiovascular-events #clinical-trial #health

health2 years ago•2 min saved

"Wegovy's Heart-Protective Effects Boost Novo Nordisk Shares"

Novo Nordisk's shares surged after late-stage trial data revealed that its obesity drug, Wegovy, reduced the risk of major cardiovascular events by 20% compared to a placebo. The results of the SELECT trial exceeded expectations and could help reshape Wegovy's perception as a "vanity drug." The trial involved over 17,600 adults with cardiovascular disease who were overweight or obese but had no history of diabetes. Novo Nordisk plans to seek regulatory approvals for an expanded label indication for Wegovy in the US and European Union this year. The detailed results of the trial will be presented at a later scientific conference.

via CNBC|

#cardiovascular-events #clinical-trial #health

health2 years ago•1 min saved

"Wegovy: A Game-Changer in Heart Disease Prevention, Boosting Novo Nordisk's Stock"

Novo Nordisk, the maker of the weight-loss drug Wegovy, shared data from a major trial showing that the drug lowers the risk of adverse cardiovascular events by 20%. The trial involved over 17,000 participants and measured data over a five-year period. The 2.4 mg dosage of Wegovy was found to be safe and well-tolerated. The announcement of the trial results caused Novo Nordisk's shares to surge by over 16%.

via Forbes|

#cardiovascular-events #health #novo-nordisk

health3 years ago•4 min saved

Vitamin D Supplements Show Promising Cardiovascular Benefits

A large prospective randomized trial called D-Health found that high monthly doses of vitamin D for 5 years did not significantly reduce the risk of cardiovascular events in adults aged 60 or older. However, there was a significant 19% reduction in the risk of myocardial infarction (MI) with vitamin D supplementation. Subgroup analysis suggested potential benefits for individuals taking statins or other cardiovascular medications. The study's authors caution against recommending vitamin D supplementation specifically for cardiovascular disease prevention, but suggest that clinicians may consider supplementing elderly individuals with underlying risk factors for CV disease. Further research is needed to understand the interactions between vitamin D supplementation and cardiovascular medications.

via Medscape|

#cardiovascular-events #coronary-revascularization #d-health-trial

health3 years ago•1 min saved

Prevalence of High Cholesterol in US Adults with Coronary Artery Disease

A study using data from the National Health and Nutrition Examination Survey (NHANES) found that a significant percentage of US adults with coronary artery disease (CAD) are not achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels. Lipid control is crucial for reducing the risk of secondary cardiovascular events in CAD patients. The study highlights the need for improved management of LDL-C levels in this population.

via JAMA Network|

#cardiovascular-events #coronary-artery-disease #guidelines